BU Today

Science & Tech

Developing a New Weapon Against HIV

MED prof: plant-grown antibodies could hold key

Deborah Anderson, HIV AIDS research, Boston University School of Medicine

MED’s Deborah Anderson is working to create a cheap and powerful new weapon against AIDS, with a $13 million grant from the National Institute of Allergy and Infectious Diseases. Photo by Kalman Zabarsky

The latest news on AIDS is sobering. In 2009, 2.6 million people became infected with HIV, according to data released in November by UNAIDS. That’s down from 3.1 million in 1999, but still amounts to 7,000 new infections and nearly 5,000 deaths every day.

Deborah Anderson is working to reverse this trend. Armed with a five-year, $13.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), the School of Medicine professor of obstetrics and gynecology and microbiology is developing an innovative approach to AIDS prevention, supplementing the body’s own immune system with novel antibodies grown in tobacco plants. If it works, her system will offer not only a cheap and powerful new weapon against AIDS, but also insights into stopping the spread of viruses from the common cold to the deadly Ebola virus.

The key to Anderson’s strategy is mucus, that lowly, slippery fluid that coats the nose, protects the eyes, and guards women’s reproductive systems from infection. An expert on mucosal immunology and HIV, Anderson has been studying these subjects for decades. For her PhD research at the University of Texas, she investigated the immunology of pregnancy, examining why a mother’s immune system doesn’t reject a fetus and why some women develop an immune response to their partner’s sperm. She garnered a deep understanding of immunology and gynecology, two subjects that became critically important when the AIDS epidemic burst onto the scene.

In the 1980s, a friend at the National Institutes of Health suggested that Anderson study the sexual transmission of HIV/AIDS, which at the time was just beginning to be understood. “I got involved when the epidemic was getting started,” she says. Since then she has specialized in genital tract immunology, examining how the body’s own immune system responds to HIV, herpes simplex virus (HSV), and other sexually transmitted diseases (STDs).

Which bring us back to mucus, a secretion that protects cells and wards off infection. Human mucus is made of long molecules called mucins; there’s some evidence that antibodies may tether themselves to mucins and also enter and remain inside skin cells lining the mucus membranes. Anderson is creating a microbicide that a woman can insert in her genital tract via an easy-to-use ring, gel, or film. The microbicide will contain two antibodies that attack different parts of the HIV virus and a third antibody that neutralizes HSV. If the technology works, in the future it could include antibodies that protect against other STDs as well.

“We could keep adding antibodies because the body makes a whole host of them,” says Anderson, pointing out that human secretions are already brimming with antibodies. “The beauty of this system is that we’re just helping Mother Nature.”


Tobacco plants offer great promise for fast, low-cost antibody production. Photo by David Hoffman

Despite the worldwide epidemic, HIV is actually a fragile virus. “It doesn’t infect very easily,” Anderson says. “If a woman has unprotected sex with an infected man, there’s only about a one in 1,000 chance of getting infected with HIV.” However, other factors can raise the risk, she adds. Genital herpes, for instance, causes inflammation and sores that allow HIV to more easily breach the body’s natural defenses, so Anderson’s microbicide is designed to guard against both HSV and HIV. She hopes this approach will tackle one of the recurring problems with microbicides and spermicides: they work, but people don’t use them. “Take condoms,” she says. “They’re very effective, but people don’t use them correctly.” She expects that the new microbicide will be easy to use and hopes it will provide protection from HIV/HSV for up to a month.

To develop the particular antibodies to be used in the microbicide, Anderson is working with biophysicist Kevin Whaley, a longtime collaborator and founder of Mapp Biopharmaceuticals, in San Diego. Mapp is a leader in the production of “plantibodies,” antibodies (in this case, HIV-specific antibodies) grown in plants. Plantibodies can be manufactured in huge amounts quickly and cheaply compared to growing similar antibodies in animals or cell cultures. “The technology has been around for over 10 years, but now it has gelled,” says Anderson. “They have been able to ramp up production and lower costs.” Tobacco in particular is easy to grow and harvest and offers great promise for fast, low-cost antibody production. The current cost of antibodies grown in mammals is about $50 a dose, while the cost of tobacco-grown antibodies will likely be much less—somewhere between 20 cents and $1 a dose.

Anderson’s grant comes from the NIH’s Integrated Preclinical/Clinical Program for HIV Topical Microbicides, created to foster collaboration between industry and academia. Anderson will oversee 6 projects at 10 institutions that will test new antibody formulations, grow the plants, harvest the antibodies, and build and test the application devices. The grant is the largest she’s ever received, and overseeing groups in both academia and industry is new for her. “This one is challenging because all the paperwork is different in working with industry,” she says.

Anderson’s first goal over the grant’s five years is to determine which configuration of antibodies works best when mixed with mucus or applied to mucosal skin cells, a process that will take about a year. Then her team will grow large batches of the chosen antibodies in tobacco plants and will test the antibodies in monkeys to see if they prevent the transmission of HIV. The grant will also include preclinical human trials to make sure the antibodies don’t cause irritation or inflammation and to see how long they remain active in the body.

“Our dream is to put plantibodies on the map for preventing transmission of STDs,” says Anderson. If the technology works, it could have far broader implications. Many other infections enter the body through mucus membranes in the nose, eyes, and lungs. If Anderson’s plantibodies work, they may offer a new weapon for preventing the spread of tuberculosis, influenza, and even that universal annoyance, the common cold.

Barbara Moran (COM’96) is a science writer in Brookline, Mass. She can be reached through her website WrittenByBarbaraMoran.com.


7 Comments on Developing a New Weapon Against HIV

  • Mark Salpinger on 01.30.2012 at 1:07 am

    A good idea, it will be interesting to see the results of the clinical trial. Some pitfalls might include:

    1. An effective immunoprophylactic strategy to combat HIV might involve using broadly neutralizing antibodies, are these the antibodies being used?

    2. Is it possible that the antibodies which would be effective at the mucosal level are completely different from what is partially effective in the blood stream and organs?

    3. There have been some disappointments with microbials and HIV prevention. Realistically, is it possible to obtain 100% mucosal coverage with the plantibodies? Especially considering the high mucosal turnover rate? While a 40% effective plantibody microbial would be a great scientific advance, on a public health level, is it ethical to produce and prescribe a medication which is only partially effective and might lure women into a state of complacency?

  • Deborah Anderson on 01.30.2012 at 11:15 am

    Thank you for the positive feedback. We are indeed pioneering this research with two of the most potent broadly neutralizing antibodies against HIV, VRC01 and 4E10. We will be testing plantibodies configured as secretory IgA molecules, a type of antibody that is normally found in mucosal secretions and not in blood, and hypothesize that they will provide better protection against STIs than IgG type antibodies found in blood. We are hopeful that our plantibody microbicide gel/ring will be more effective than the microbicide products tested to date.

  • Mark Salpinger on 01.31.2012 at 5:05 am

    Thank you for the response, you are certainly completing fascinating research. My question regarding using IgA mucosal antibodies is that broadly neutralizing antibodies such as VRCO1 were first identified in blood (?). I guess they have isolated IgA antibodies from mucosal secretions, but I wonder if anyone has looked at mucosal secretions in attempt to identify which specific IgAs are involved in a protective response at the mucosal level. Such as in the case where VRCO1 in IgG form circulating in the blood slows down HIV progression, whereas VRCO1 in IgA form is simply a “byproduct” of the immune response to HIV?

    I guess the “proof in the pudding” will be continued tests in monkeys.

    Also, I guess I would theoretically be concerned when designing the clinical trial as IUDs increase the risk of HIV (?), and so a vaginal ring might lead to increased mucosal inflammation and increased risk of HIV infection?

    Amazing work as it could potentially save millions of lives!

  • Lisa on 01.31.2012 at 3:14 pm

    Just wondering where the first link in the story is supposed to go — it doesn’t seem to work.


    • BU Today on 01.31.2012 at 3:30 pm

      That link is fixed now, Lisa. Goes to UNAIDS data and analysis pages.

  • Ivan Sanchez on 04.11.2012 at 12:24 am

    What are the possibilities of HIV creating some sort of resistance to this?

  • Bemgba Nyakuma on 07.04.2012 at 12:51 pm

    Interesting research. It will be nice to know what compounds in the so-called plantibodies are effective in combating the HIV virus. Perhaps also a study can be carried out to see if there exists a correlation between casual or chain smokers and HIV prevalence. That way the scientists can also test the efficacy of the tobacco based plantibodies. I think that’ll be worth trying too.

Post Your Comment

(never shown)